Collectively, our findings suggest that different components of the 19S regulatory complex in the 26S proteasome have indications for OS and may serve as prognostic biomarkers and novel therapeutic targets in FLT3-mutated AML and other types of cancers. Here, FLT3 is linked to cancer.